Jaguar Health Inc. (JAGX) stock prices surged by 9.39% some time after market trading commenced on October 22nd 2021. This brought the price per share up to USD$1.98 early on in the trading day.
Approval for Merger
October 25th 2021 saw JAGX stock announce the completion of the legally required Golden Powers process, which is legally required. The Golden Powers process was implemented by the Italian government as a response to the ongoing coronavirus pandemic. It is aimed at pharmaceutical transactions with foreign participation, in this case resulting in the company’s merger with Napo EU S.p.A. and Dragon SPAC S.p.A. to be effective within the next week. Following the Italian governments clearance for the merger, the combined entity will have the exclusive license agreement with Jaguar to the Crofelemer pipeline in Europe. This requires typical up-front license fees, milestone payments, royalties, and a drug supply agreement.
JAGX stock also holds a substantial majority equity interest in the combined entity, which will keep the name Nap EU S.p.A. The company forecasts Napo EU to be listed on the European exchange. September 15th, 2021 saw the European Medicines Agency confirm the receipt of the Orphan Drug Designation application for Crofelemer for short bowel syndrome (SBS). The treatment has been granted the Orphan Drug Designation by the United States Food and Drug Administration. Napo EU’s starting efforts will be geared towards the conditional marketing authorization pathway for the EMA for Crofelemer in SBS with intestinal failure.
About JAGX Stock
The commercial stage pharmaceutical company aims to develop innovative, plant-based, non-opioid, and sustainable derived prescription medicines. These treatments are geared towards GI distress, with a particular focus on chronic, debilitating diarrhea. JAGX stock’s wholly owned subsidiary, Napo Pharmaceuticals, focuses on the development and commercialization of proprietary plant-based human gastrointestinal pharmaceuticals, which are made from plants harvested ethically from various rainforest areas. The company’s Mytesi product has been approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Future Outlook for JAGX Stock
JAGX stock is poised to capitalize on the expanded scope of opportunities afforded to it as a result of the approved merger. The company is keen to maintain the momentum generated by this development in a bid to usher in unprecedented growth. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal. This is hoped to facilitate significant and sustained increases in shareholder value over time.